Chen Hu

Assistant Professor

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China

Tel:+86-551-65595117

Email: chenh@hmfl.ac.cn

Education Background

2015/09—2018/11 University of Science and technology of China, PhD

2007/09—2010/06 University of Science and technology of China, life science, M.S

2003/09—2007/06 Hefei University of Technology, school of B.S

Research Experience

2018/12-2021/12  Postdoc Fellow, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences

2012/08-2015/09  Research Assistant, High Magnetic Field Laboratory, Chinese Academy of Sciences

Publications

  1. Chen Hu#, Aoli Wang#, Hong Wu#, Ziping Qi#, Xixiang Li#, Xiao-E Yan#, Cheng Chen, Kailin Yu, Fengming Zou, Wenchao Wang, Wei Wang, Jiaxin Wu, Juan Liu, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, Qingsong Liu.* Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode. Oncotarget 2017, 8(11): 18359-18372. doi: 10.18632/oncotarget.15443
  2. Hong Wu＃， Qiong Huang＃， Ziping Qi＃， Yongfei Chen＃, Aoli Wang, Cheng Chen, Qianmao Liang, Jinghua Wang, Wensheng Chen, Jin Dong, Kailin Yu, Chen Hu, Wenchao Wang, Xiaochuan Liu, Xiaoxiang Li, Nathanael S. Gray, Jing Liu*, Wei Wei*, Qingsong Liu*. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Scientific Reports 2017, DOI: 10.1038/s41598-017-00482-4.
  3. Aoli Wang#, Xixiang Li#, Hong Wu#, Fengming Zou#, Xiao-E Yan#, Cheng Chen, Chen Hu, Kailin Yu, Wenchao Wang, Peng Zhao, Jiaxin Wu, Ziping Qi, Wei Wang, Beilei Wang, Li Wang, Tao Ren, Shanchun Zhang, Cai-Hong Yun*, Jing Liu*, and Qingsong Liu*. Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutants Kinase Inhibitor with a Distinct Binding Mode. J. Med. Chem. 2017, DOI: 10.1021/acs.jmedchem.6b01907.
  4. Qiang Wang＃, Feiyang Liu＃, Beilei Wang＃, Fengming Zou＃, Ziping Qi, Cheng Chen, Kailin Yu, Chen Hu, Shuang Qi, Wenchao Wang, Zhenquan Hu, Juan Liu, Wei Wang, Li Wang, Qianmao Liang, Shanchun Zhang, Tao Ren, Qingsong Liu*,Jing Liu*. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl) phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding. J. Med. Chem. 2017, 60(1): 273–289.
  5. Aoli Wang＃, Xiao-E Yan＃, Hong Wu＃, Wenchao Wang, Chen Hu, Cheng Chen, Zheng Zhao, Peng Zhao, Xixiang Li, Li Wang, Beilei Wang, Zi Ye, Jinhua Wang, Chu Wang, Wei Zhang, Nathanael S. Gray, Ellen L. Weisberg, Liang Chen, Jing Liu*,Cai-Hong Yun*, Qingsong Liu*. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 2016, 7(43): 69760-69769.
  6. Binhua Li#, Aoli Wang#, Juan Liu#, Ziping Qi#, Xiaochuan Liu#, Kailin Yu, Hong Wu, Cheng Chen, Chen Hu, Wenchao Wang, Jiaxin Wu, Zhenquan Hu, Ling Ye, Fengming Zou, Feiyang Liu, Beilei Wang, Li Wang, Tao Ren, Shaojuan Zhang, Mingfeng Bai, Shanchun Zhang, Jing Liu*, Qingsong Liu*. Discovery of N-((1-(4-(3-(3-((6,7-dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase. J. Med. Chem. 2016, 59(18): 8456-8472.
  7. Lei Zhang#, Jihao Wang#, HongLei Wang, Wenchao Wang, Zhiyuan Li, Juanjuan Liu, Xingxing Yang, Xinmiao Ji, Yan Luo, Chen Hu, Yubin Hou, Qianqian He, Jun Fang, Junfeng Wang, Qingsong Liu, Guohui Li, Qingyou Lu, Xin Zhang*. Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation. Oncotarget 2016, 7(27): 41527-41539.
  8. Aoli Wang#, Hong Wu#, Cheng Chen#, Chen Hu#, Ziping Qi#, Wenchao Wang, Kailin Yu, Xiaochuan Liu, Fengming Zou, Zheng Zhao, Jiaxin Wu, Juan Liu, Feiyang Liu, Wang Li, Richard M. Stone, Ilene A. Galinksy, James D. Griffin4, Shanchun Zhang, Ellen L. Weisberg*, Jing Liu*, Qingsong Liu *. Dual Inhibition of AKT/FLT3-ITD by A674563 Overcomes FLT3 Ligand-Induced Drug Resistance in FLT3-ITD positive AML. Oncotarget 2016, 7(20): 29131-42.
  9. Hong Wu#, Chen Hu#, Aoli Wang#, Ellen L. Weisberg#, Yongfei Chen, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M. Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu*, Nathanael S. Gray*, Liu Qingsong*. Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia. Leukemia 2016, 30(1): 173-81.
  10. Wu Hong#, Chen Hu#, Wang Aoli#, E L Weisberg#, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin,Liu Jing* and Liu Qingsong*. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 2016, 30(3): 754-7.
  11. Xixiang Li#, Aoli Wang#, Kailin Yu#, Ziping Qi#, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Liu Qingsong*. Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino) ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia. J. Med. Chem. 2015, 58(24): 9625-38.

 

Patents

  1. "Triciribine and its metabolite is sensitive to FLT3-ITD dependent AML!",  Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong;Wang Wenchao; Chen Cheng;Hu Chen;Li Binhua; Ziping Qi; Yu Kailin;Wang Li. (2015)
  2. "A new type of FLT3 kinase inhibitors and its application!",  Liu, Qingsong; Liu Jing;Li Binhua;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Yu Kailin;Wang Beilei; Wang Li. (2015)
  3. "FLT3 kinase new inhibitors and its application!",  Liu, Qingsong; Liu Jing;Li Xixiang;Wang Aoli; Wu Hong; Chen Cheng;Wang Wenchao; Hu Chen; Zhao Zheng; Wu Jiaxin; Liu Juan;Yu Kailin; Wang Wei; Wang Li; Wang Beilei. (2015)
  4. "A674563 is sensitive to FLT3-ITD dependent AML !",  Liu, Qingsong; Liu Jing;Wang Aoli; Wu Hong; Chen Cheng; Hu Chen; Wang Wenchao; Liu Xiaochuan; Yu Kailin; Zhao Zheng; Wu Jiaxin; Liu Juan; Wang Li; Wang Beilei. (2015)
  5. "New application of Ibrutinib",   Liu, Qingsong; Liu Jing; Wang Beilei; Wang Aoli; Wu Hong; Hu Chen; Wang Wenchao; Chen Cheng; Wang Li; Li Xixiang; Li Xiaoxiang; Xu Ziao.(2015)
  6. "New class of Bruton's tyrosine kinase inhibitors",   Liu, Qingsong; Liu Jing; Chen Yongfei; Wu Hong; Wang Aoli; Wang Beilei; Hu Chen; Wang Wenchao; Chen Cheng.(2015)
  7. "Ibrutinib is sensitive to FLT3-ITD dependent AML", Liu, Qingsong; Liu Jing; Wu Hong; Hu Chen; Wang Aoli; Wang Wenchao; Chen Cheng; Li Xixiang; Zhao Zheng; Wang Li; Wang Beilei.(2014)